GLP1R and obesity disorder: Although American Diabetes Association in according to its new updates release, Glucagon-like Peptide 1 (GLP-1) receptor agonists demonstrated benefits in adults with type 2 diabetes, with overweight or obesity, in countries such as México, is still a primary treatment (American Diabetes Association Professional Practice Committee, 2024).